CEACAM5 and colorectal cancer: In 1996, a 99mTc-labeled anti-CEA Fab’ fragment (arcitumomab; CEA-Scan; Immunomedics, Inc.)was approved by the United States Food and Drug Administration (FDA) for colorectal cancer imaging.